Antibodies

28 Oct 2019 Imfinzi and Imfinzi plus tremelimumab delayed disease progression in Phase III POSEIDON trial for 1st-line treatment of Stage IV non-small cell lung cancer
28 Oct 2019 Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions
28 Oct 2019 NeoTX Announces First Patient Dosed in Phase 1b Trial of Naptumomab Estafenatox (Nap) in Combination with Durvalumab in Solid Tumors
28 Oct 2019 Y-mAbs Announces Positive Omburtamab Clinical Data
28 Oct 2019 Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 50% of Total Patient Enrollment
28 Oct 2019 Zymeworks Announces Phase 1 Data for ZW25 in Combination with Chemotherapy in Advanced Gastroesophageal Adenocarcinoma at AACR-NCI-EORTC International Conference
28 Oct 2019 Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA
28 Oct 2019 Formycon announces Start of Phase I Clinical Trial with Ustekinumab Biosimilar candidate FYB202
27 Oct 2019 Adagene Presents Its Lead Antibody Program, ADG106, at International Conferences
25 Oct 2019 MacroGenics Announces Initiation of Phase 2/3 MAHOGANY Study of Margetuximab in Gastric or Gastroesophageal Junction Cancer
25 Oct 2019 Y-mAbs Announces Naxitamab Update
25 Oct 2019 European Commission Approves Opdivo (nivolumab) Four-Week Dosing Schedule for the Adjuvant Treatment of Adult Patients with Melanoma with Involvement of Lymph Nodes or Metastatic Disease Who Have Undergone Complete Resection
24 Oct 2019 FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer
24 Oct 2019 ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43
24 Oct 2019 Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis
23 Oct 2019 Janssen Seeks to Expand Use of TREMFYA (guselkumab) in the Treatment of Adults With Active Psoriatic Arthritis
22 Oct 2019 Exploratory Analysis Reports Efficacy and Safety of BAVENCIO® (avelumab) Over Three Years in Previously Treated Metastatic Merkel Cell Carcinoma
22 Oct 2019 CheckMate -9LA, a Phase 3 Trial Evaluating Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Combined with Chemotherapy, Meets Primary Endpoint Demonstrating Superior Overall Survival Compared to Chemotherapy Alone in First-Line Lung Cancer
22 Oct 2019 Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
22 Oct 2019 Aslan Pharmaceuticals enrolls first patient in proof-of-concept study for ASLAN004 targeting atopic dermatitis
21 Oct 2019 Janssen Announces U.S. FDA Approval of STELARA® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
21 Oct 2019 New subcutaneous formulation of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) shows positive Phase 1 results for the treatment of IBD in data presented at UEG Week Barcelona 2019
21 Oct 2019 Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies and Appoints George Golumbeski as Chairman of the Board
21 Oct 2019 Genentech’s Tecentriq in Combination With Avastin Increased Overall Survival and Progression-Free Survival in People With Unresectable Hepatocellular Carcinoma
19 Oct 2019 Alexion Receives FDA Approval for ULTOMIRIS® (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top